|
| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Orphan Drug
|
2018
|
NIAMS
|
5R44AR061900-03
|
|
Development of a Porcine Model of Duchenne Muscular Dystrophy
|
ROGERS, CHRISTOPHER
|
EXEMPLAR GENETICS, LLC
|
IA
|
$150,613
|
|
Orphan Drug
|
2018
|
NIAID
|
1K22AI125474-01
|
|
Mechanisms by which insect specific flaviviruses are host restricted and preclude super-infection with pathogenic flaviviruses
|
AUGUSTE, ALBERT
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
VA
|
$159,950
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA172582-05
|
|
Alpha Radioimmunotherapy for Lymphoma Treatment
|
SANDMAIER, BRENDA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$634,846
|
|
Orphan Drug
|
2018
|
NINDS
|
5R01NS083813-05
|
|
Molecular Mechanisms Controlling Wallerian Degeneration of Axons
|
TESSIER-LAVIGNE, MARC
|
STANFORD UNIVERSITY
|
CA
|
$357,147
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA194783-04
|
|
Computational modeling of tumor burden by CT to advance cancer therapeutics
|
MAITLAND, MICHAEL
|
INOVA HEALTH CARE SERVICES
|
VA
|
$573,026
|
|
Orphan Drug
|
2018
|
NCI
|
5U01CA199221-05
|
|
Osteosarcoma: Patient Derived Xenograft Preclinical Testing
|
GORLICK, RICHARD
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$136,071
|
|
Orphan Drug
|
2018
|
NCI
|
1K22CA214849-01
|
|
The role of the histone chaperone Chaf1b in sustaining the Hoxa9-driven AML differentiation block
|
BLANCO, MARIO
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$191,970
|
|
Orphan Drug
|
2018
|
NCI
|
1K22CA216008-01
|
|
G0S2 in Chronic Myeloid Leukemia Disease Progression and Imatinib Resistance
|
EIRING, ANNA
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
TX
|
$193,030
|
|
Orphan Drug
|
2018
|
NCI
|
5R35CA197718-04
|
|
Dynamic Complexity of Brain Tumor Stem Cells
|
RICH, JEREMY
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$862,008
|
|
Orphan Drug
|
2018
|
NINDS
|
7R01NS081125-04
|
|
Aurora-A is a novel therapeutic target in glioblastoma
|
LEHMAN, NORMAN
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$359,357
|
|
Orphan Drug
|
2018
|
NINDS
|
1R43NS100227-01A1
|
|
Nonsense Suppressing Drugs for Rett Syndrome
|
KOZIKOWSKI, ALAN
|
STARWISE THERAPEUTICS, LLC
|
IL
|
$282,726
|
|
Orphan Drug
|
2018
|
FIC
|
1R21TW010592-01
|
|
Combined Phone based video DOT and mobile payments for TB treatment in Cambodia
|
YOONG, JOANNE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$77,237
|
|
Orphan Drug
|
2018
|
OD
|
1R21TW010592-01
|
|
Combined Phone based video DOT and mobile payments for TB treatment in Cambodia
|
YOONG, JOANNE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$77,236
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA194742-03
|
|
Reolysin-based combination therapy in relapsed multiple myeloma
|
PICHIORRI, FLAVIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$574,645
|
|
Orphan Drug
|
2018
|
NCATS
|
5U54HD061222-14
|
8881
|
Rett-related disorders: Longitudinal studies, Biomarker and Clinical Outcome development.
|
PERCY, ALAN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$130,588
|
|
Orphan Drug
|
2018
|
NICHD
|
5U54HD061222-14
|
8881
|
Rett-related disorders: Longitudinal studies, Biomarker and Clinical Outcome development.
|
PERCY, ALAN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$88,800
|
|
Orphan Drug
|
2018
|
NINDS
|
5U54HD061222-14
|
8881
|
Rett-related disorders: Longitudinal studies, Biomarker and Clinical Outcome development.
|
PERCY, ALAN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$41,788
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA195613-21
|
|
Molecular Mechanisms and Therapeutic Approaches to Malignant Gliomas
|
HUNTER, TONY
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
CA
|
$671,581
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI103055-05
|
|
Innate and early B cell responses to V. cholerae
|
HARRIS, JASON
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$750,907
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI123341-02
|
|
Mechanisms Governing Translational Regulation During Plasmodium Transmission
|
LINDNER, SCOTT
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
PA
|
$386,419
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI114685-04
|
|
Hit-to-lead discovery for sleeping sickness via industry-academic partnership
|
POLLASTRI, MICHAEL
|
NORTHEASTERN UNIVERSITY
|
MA
|
$475,385
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA202919-03
|
|
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
|
ZHANG, RUGANG
|
WISTAR INSTITUTE
|
PA
|
$434,625
|
|
Orphan Drug
|
2018
|
NIGMS
|
5R01GM103790-03
|
|
Receptor and Carriers for Coupled Ion Transport
|
SESSLER, JONATHAN
|
UNIVERSITY OF TEXAS, AUSTIN
|
TX
|
$300,186
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA200624-03
|
|
Cytoplasmic Multimerization of the RNA-binding protein HuR is Oncogenic in Glioma
|
NABORS, LOUIS
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$342,804
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA190688-03
|
|
SON-mediated gene expression and leukemia
|
AHN, ERIN
|
UNIVERSITY OF SOUTH ALABAMA
|
AL
|
$346,556
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA194058-03
|
|
Painted erythrocyte carriers for therapy of acute myeloid leukemia
|
SIMBERG, DIMITRI
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$352,151
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI127823-02
|
|
Drug discovery against lyssaviruses by high thoughput screening
|
SCHNELL, MATTHIAS
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$384,375
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA201230-04
|
|
The role of H3K79 methylation in IDH-mutant leukemia
|
BERNT, KATHRIN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$438,616
|
|
Orphan Drug
|
2018
|
NICHD
|
5R01HD086195-03
|
|
Smart targeting nano-theranostics for image-guided drug delivery to pediatric brain tumors
|
LI, YUANPEI
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
CA
|
$325,775
|
|
Orphan Drug
|
2018
|
NINDS
|
5R01NS099463-02
|
|
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
NC
|
$347,813
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069421-12
|
|
GHESKIO HIV Clinical Trial Unit
|
PAPE, JEAN
|
GHESKIO CENTER
|
HAITI
|
$1,037,231
|
|
Orphan Drug
|
2018
|
NINDS
|
5R01NS094388-02
|
|
Tissue Engineered Human Neuromuscular Junctions for Modeling Axonal Neuropathy
|
KIM, DEOK-HO
|
UNIVERSITY OF WASHINGTON
|
WA
|
$331,800
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA128943-10
|
|
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
NY
|
$396,625
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127634-02
|
|
Novel Inhibitors of Cruzain and Trypanosoma brucei Cathpesin B as Potential Drug Candidates for the Treatment of African Trypanosomiasis and Chagas Disease
|
MEEK, THOMAS
|
TEXAS A&M AGRILIFE RESEARCH
|
TX
|
$189,280
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA193981-03
|
|
KLF9-dependent pathways in multiple myeloma drug resistance
|
NIKIFOROV, MIKHAIL
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$392,306
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA178393-03
|
|
Genomic Architecture of LGL Leukemia
|
LOUGHRAN, THOMAS
|
UNIVERSITY OF VIRGINIA
|
VA
|
$609,097
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA194090-03
|
|
Treatment of multiple myeloma using oncolytic myxoma virus
|
BARTEE, ERIC
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$341,981
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069503-12
|
|
Terry Beirn CPCRA Clinical Trials Unit
|
KAN, VIRGINIA
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$4,090,330
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA193895-03
|
|
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy
|
SLUSHER, BARBARA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$425,618
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA195718-03
|
|
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials
|
HOLLAND, ERIC
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$633,241
|
|
Orphan Drug
|
2018
|
NINDS
|
5R21NS099962-02
|
|
Developing novel treatment strategies for Spinocerebellar ataxia type 1
|
OPAL, PUNEET
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$197,500
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069521-12
|
|
Stellenbosch University Clinical Trials Unit (SUN-CTU)
|
COTTON, MARK
|
STELLENBOSCH UNIVERSITY TYGERBERG CAMPUS
|
SO AFR
|
$1,338,611
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069463-12
|
|
Clinical Trials Units for NIAID Networks (UM1)
|
SANNE, IAN
|
WITS HEALTH CONSORTIUM (PTY), LTD
|
SO AFR
|
$1,084,670
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA194064-04
|
|
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy
|
MING, XIN
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$283,650
|
|
Orphan Drug
|
2018
|
NINDS
|
5K08NS096117-02
|
|
Next-Generation Diagnostics for Acute Encephalitis
|
WILSON, MICHAEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$199,737
|
|
Orphan Drug
|
2018
|
NIA
|
5R01NS095969-03
|
|
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker
|
WONG, PHILIP
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$50,625
|
|
Orphan Drug
|
2018
|
NINDS
|
5R01NS095969-03
|
|
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker
|
WONG, PHILIP
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$354,375
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069422-12
|
|
South African Medical Research Council Clinical Trials Unit (MRC CTU)
|
RAMJEE, GITA
|
MEDICAL RESEARCH COUNCIL OF SOUTH AFRICA
|
SO AFR
|
$1,084,670
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI118224-03
|
|
Small-Molecule Antibiotics Targeting Siderophore Biosynthesis in M. tuberculosis
|
TAN, DEREK
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$666,740
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069530-12
|
|
Johns Hopkins University Kampala-Nanning Clinical Trial Unit
|
FOWLER, MARY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$1,256,808
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA193675-03
|
|
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer
|
PAL, SOUMITRO
|
BOSTON CHILDREN'S HOSPITAL
|
MA
|
$404,888
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA201719-03
|
|
A Novel Positron Emission Tomography Strategy for Early Detection and Treatment Monitoring of Graft-versus-host Disease
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
CA
|
$361,510
|
|
Orphan Drug
|
2018
|
NINDS
|
5R01NS097147-02
|
|
Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic disease
|
JAIN, POOJA
|
DREXEL UNIVERSITY
|
PA
|
$431,433
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069469-12
|
|
CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment
|
ABDOOL KARIM, QUARRAISHA
|
CENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA
|
SO AFR
|
$1,287,739
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI116605-03
|
|
Mechanisms of Mycobacterium Tuberculosis pH-driven Adaptation
|
ABRAMOVITCH, ROBERT
|
MICHIGAN STATE UNIVERSITY
|
MI
|
$380,510
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI077538-09
|
|
The roles of polyphosphate and acidocalcisomes in Trypanosoma brucei
|
DOCAMPO, ROBERTO
|
UNIVERSITY OF GEORGIA
|
GA
|
$375,000
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI121782-02
|
|
Cholera conjugates designed to prevent colonization and induce B cell memory
|
WADE, WILLIAM
|
DARTMOUTH COLLEGE
|
NH
|
$199,400
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA143130-08
|
|
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses
|
NAKAGAWA, MAYUMI
|
UNIV OF ARKANSAS FOR MED SCIS
|
AR
|
$721,272
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA014089-43
|
8288
|
Molecular Genetics Research Program (Project-001)
|
LIEBER, MICHAEL
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$70,375
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA014089-43
|
8290
|
Tumor Microenvironment Research Program (Project-003)
|
DECLERCK, YVES
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$70,375
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA014089-43
|
8293
|
Gastrointestinal Cancers Research Program (Project-006)
|
KAHN, MICHAEL
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$70,375
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA189986-04
|
|
KSHV alteration of cellular metabolism
|
LAGUNOFF, MICHAEL
|
UNIVERSITY OF WASHINGTON
|
WA
|
$342,143
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL130336-03
|
|
Targeting Choline Phospholipid Metabolism in Lymphangioleiomyomatosis
|
PRIOLO, CARMEN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$436,000
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069438-12
|
|
IMPACTA PERU CLINICAL TRIALS UNIT
|
LAMA, JAVIER
|
ASOCIACION CIVIL IMPACTA SALUD Y EDUCACN
|
PERU
|
$1,693,877
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069418-12
|
|
Emory- Duke- Orlando- CDC (EmDOC) Clinical Trials Unit
|
LENNOX, JEFFREY
|
EMORY UNIVERSITY
|
GA
|
$2,783,692
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069476-11
|
|
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit
|
GRINSZTEJN, BEATRIZ
|
FUNDACAO OSWALDO CRUZ
|
BRAZIL
|
$773,601
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI075045-09
|
|
Resistance of Malaria Parasites to Artemisinin-Based Therapies
|
ROSENTHAL, PHILIP
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$516,295
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA182461-05
|
|
Defining the impact of clonal evolution on chronic lymphocytic leukemia
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
MA
|
$362,378
|
|
Orphan Drug
|
2018
|
NIDDK
|
5R01DK066485-11
|
|
Structural Basis of KATP Channel Gating
|
SHYNG, SHOW
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$346,500
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA176001-05
|
|
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis
|
GROSSNIKLAUS, HANS
|
EMORY UNIVERSITY
|
GA
|
$323,700
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069496-12
|
|
San Francisco Bay Clinical Trials Unit
|
BUCHBINDER, SUSAN
|
PUBLIC HEALTH FOUNDATION ENTERPRISES
|
CA
|
$1,493,196
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI123272-02
|
|
Development of a single-dose rabies virus vaccine
|
MCGETTIGAN, JAMES
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$390,000
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA136494-10
|
|
Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle
|
MUKHERJEE, PRIYABRATA
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$304,695
|
|
Orphan Drug
|
2018
|
NCI
|
5R00CA188259-04
|
|
Regulation of cancer cell metabolism and growth by the pancreatic tumor stroma
|
SHERMAN, MARA
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$249,000
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA199725-03
|
|
avb6-directed molecular imaging and therapy
|
SUTCLIFFE, JULIE
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
CA
|
$488,662
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA202846-03
|
|
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles
|
YANG, LILY
|
EMORY UNIVERSITY
|
GA
|
$411,268
|
|
Orphan Drug
|
2018
|
NICHD
|
5R01HD082127-04
|
|
Behavioral Inflexibility in IDD Outcome Measurement
|
BOYD, BRIAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$62,464
|
|
Orphan Drug
|
2018
|
NINDS
|
5F30NS100217-02
|
|
Mechanisms Underlying the Pathogenic Role of an α-Adducin/α2-Na/K ATPase Complex in Amyotrophic Lateral Sclerosis
|
SMITH, SARAH
|
WASHINGTON UNIVERSITY
|
MO
|
$31,208
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI116943-03
|
|
A systematic analysis of small RNA interactions during RNA virus infections
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$706,055
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI127456-02
|
|
Poxvirus manipulation of the host cell protein synthesis machinery
|
WALSH, DEREK
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$395,000
|
|
Orphan Drug
|
2018
|
NINDS
|
2R37NS057553-12
|
|
Investigating Pathogenic Mechanisms of Frontotemporal Dementia Caused by Mutations in CHMP2B and TBK1
|
GAO, FEN-BIAO
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$594,625
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI056312-12
|
|
Function of antimalarial drug resistance proteins
|
ROEPE, PAUL
|
GEORGETOWN UNIVERSITY
|
DC
|
$413,757
|
|
Orphan Drug
|
2018
|
NIAID
|
5UM1AI069453-12
|
|
KARABELO Clinical Trials Unit for NIAID Networks
|
GRAY, GLENDA
|
WITS HEALTH CONSORTIUM (PTY), LTD
|
SO AFR
|
$1,461,054
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI113266-03
|
|
Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and Prevention
|
NUERMBERGER, ERIC
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$881,258
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI122753-03
|
|
Systematic evaluation of B. pertussis ACT’s role as a protective antigen
|
MAYNARD, JENNIFER
|
UNIVERSITY OF TEXAS, AUSTIN
|
TX
|
$375,718
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI128175-02
|
|
Toward an Pan-lyssavirus vaccine
|
SCHNELL, MATTHIAS
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$234,000
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA195519-03
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$238,425
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA201184-03
|
|
Biologic and Therapeutic Significance of miR-155 in AML
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$549,553
|
|
Orphan Drug
|
2018
|
NIGMS
|
5R01GM107465-04
|
|
Molecular principles of translation termination
|
KOROSTELEV, ANDREI
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$322,438
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL125228-04
|
|
Mineralocorticoid receptor and abdominal aortic aneurysm
|
GONG, MING
|
UNIVERSITY OF KENTUCKY
|
KY
|
$519,619
|
|
Orphan Drug
|
2018
|
NIGMS
|
5R01GM099836-06
|
|
Defining the mechanistic basis of a prion disaggregase
|
SHORTER, JAMES
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$339,308
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA211125-02
|
|
Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus
|
KURIE, JONATHAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$376,867
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA190617-04
|
|
Itraconazole Analogues to Treat Medulloblastoma
|
HADDEN, MATTHEW
|
UNIVERSITY OF CONNECTICUT STORRS
|
CT
|
$382,211
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA014195-45
|
7749
|
PL Mouse
|
HUNTER, TONY
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
CA
|
$43,092
|
|
Orphan Drug
|
2018
|
NINDS
|
5R35NS097263-02
|
|
Innovating Yeast and Human Genetics Approaches to Define Mechanisms of Neurodegenerative Disease
|
GITLER, AARON
|
STANFORD UNIVERSITY
|
CA
|
$1,027,273
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA016058-42
|
5094
|
Clinical Protocol and Data Management (Core 017)
|
DEVINE, STEVEN
|
OHIO STATE UNIVERSITY
|
OH
|
$491,214
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA016058-42
|
5098
|
Leukemia Research Program (LR)
|
BYRD, JOHN
|
OHIO STATE UNIVERSITY
|
OH
|
$65,564
|
|
Orphan Drug
|
2018
|
NINDS
|
5R35NS097275-02
|
|
Molecular Genetic Insight into Neurodegenerative Disease from Drosophila
|
BONINI, NANCY
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$703,113
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127635-02
|
|
Identification of preclinical drug candidates for the treatment of schistosomiasis
|
WILLIAMS, DAVID
|
RUSH UNIVERSITY MEDICAL CENTER
|
IL
|
$169,545
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI118351-02
|
|
Role of M. tuberculosis error-prone DNA polymerase DnaE2 in mutagenesis and drug resistance
|
MCDONOUGH, KATHLEEN
|
WADSWORTH CENTER
|
NY
|
$203,062
|
|
Orphan Drug
|
2018
|
NINDS
|
5K08NS096219-02
|
|
Global AAV gene therapy of Tay-Sachs disease in sheep.
|
EDWARDS, HEATHER
|
AUBURN UNIVERSITY AT AUBURN
|
AL
|
$169,128
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI123245-02
|
|
Community-directed vector control to enhance mass drug administration for onchocerciasis elimination in Africa
|
UNNASCH, THOMAS
|
UNIVERSITY OF SOUTH FLORIDA
|
FL
|
$520,781
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA042324-31
|
|
Astatine And Iodine Radiolabeled Monoclonal Antibodies
|
ZALUTSKY, MICHAEL
|
DUKE UNIVERSITY
|
NC
|
$455,654
|
|
Orphan Drug
|
2018
|
NIDDK
|
5R01DK105434-03
|
|
Investigating Autophagy in GSD-Ia
|
KOEBERL, DWIGHT
|
DUKE UNIVERSITY
|
NC
|
$320,889
|
|
Orphan Drug
|
2018
|
NINDS
|
5K08NS099427-02
|
|
Targeting ATRX-Deficient Pediatric GBM
|
KOSCHMANN, CARL
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$163,263
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA016086-42
|
8610
|
Animal Models
|
WEISSMAN, BERNARD
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$312,517
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA016086-42
|
8627
|
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)
|
DEES, ELIZABETH
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$287,365
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA016086-42
|
8629
|
Immunology Research Program (Program 2)
|
SERODY, JONATHAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$39,437
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA175380-05
|
|
FoxM1 in liver cancer.
|
RAYCHAUDHURI, PRADIP
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$405,146
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA157490-08
|
|
Investigating the Role of Autophagy in Pancreatic Cancer Radiation Resistance
|
KIMMELMAN, ALEC
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$402,563
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI128215-02
|
|
A systems analysis of drug tolerance in Mycobacterium tuberculosis
|
BALIGA, NITIN
|
INSTITUTE FOR SYSTEMS BIOLOGY
|
WA
|
$912,707
|
|
Orphan Drug
|
2018
|
NIDDK
|
5F30DK101230-04
|
|
Characterizing Isu Scaffolding Protein and ISC Multiprotein Complex Structure and
|
DZUL, STEPHEN
|
WAYNE STATE UNIVERSITY
|
MI
|
$49,524
|
|
Orphan Drug
|
2018
|
NIDDK
|
5R01DK103854-03
|
|
U2AF1 mutations in myelodysplastic syndromes: from mechanism to therapy
|
BRADLEY, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$396,105
|
|
Orphan Drug
|
2018
|
NIMH
|
5R01MH106656-03
|
|
Disrupted auditory cortical plasticity and behavior in a model of Rett syndrome
|
SHEA, STEPHEN
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$518,964
|
|
Orphan Drug
|
2018
|
NIAID
|
5F30AI118342-03
|
|
Intercellular spread of Burkholderia and novel therapeutic strategies
|
BULTERYS, PHILIP
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$44,770
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127622-02
|
|
Targeting Plasmodium apicoplast DNA replication for the treatment and prevention of malaria
|
NELSON, SCOTT
|
IOWA STATE UNIVERSITY
|
IA
|
$195,919
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA158073-07
|
|
The Role of ATM in Suppression of Lymphomas
|
ZHA, SHAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$380,000
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA142779-08
|
|
PD-1/PD-L1 modulation in cancer therapy
|
PARDOLL, DREW
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$488,332
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA196631-03
|
|
A network platform to connect drug response and prognosis phenotypes for cancers
|
LI, HU
|
MAYO CLINIC ROCHESTER
|
MN
|
$395,911
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL130533-03
|
|
Identifying Therapeutic Targets for RNA Splicing-Related Cardiomyopathy
|
CONKLIN, BRUCE
|
J. DAVID GLADSTONE INSTITUTES
|
CA
|
$456,506
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA016042-43
|
6733
|
Tumor Immunology
|
GASSON, JUDITH
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$46,785
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA016042-43
|
6743
|
Early Phase Clinical Research Support
|
GASSON, JUDITH
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$106,469
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI128311-02
|
|
A novel nanobody with good druggability to prevent and treat MERS-CoV infection
|
DU, LANYING
|
NEW YORK BLOOD CENTER
|
NY
|
$219,500
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI128517-02
|
|
Novel antitrypanosomal alkaloids for Chagas disease
|
TAN, DEREK
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$244,800
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127594-02
|
|
Lead optimization of agents targeting multiple kinetoplastid parasites
|
POLLASTRI, MICHAEL
|
NORTHEASTERN UNIVERSITY
|
MA
|
$266,948
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127505-02
|
|
Development of Gallinamide A-Inspired Agents for the Treatment of Chagas’ Disease
|
GERWICK, WILLIAM
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$227,593
|
|
Orphan Drug
|
2018
|
NCI
|
5R03CA212800-02
|
|
Advancing Treatments for Pediatric Craniopharyngioma (ATPC): Preliminary Assessment of the Cyst Fluid Inflammatory Milieu
|
HANKINSON, TODD
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$77,750
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA204979-02
|
|
Mechanisms of inv(16) acute myeloid leukemia
|
CASTILLA, LUCIO
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$436,263
|
|
Orphan Drug
|
2018
|
NIDDK
|
5R01DK107716-03
|
|
Regulation of the telomerase RNA component in hematopoiesis
|
AGARWAL, SUNEET
|
BOSTON CHILDREN'S HOSPITAL
|
MA
|
$398,250
|
|
Orphan Drug
|
2018
|
NIGMS
|
5R01GM067871-15
|
|
Structural Requirements for Sterol 14alpha-Demethylases
|
LEPESHEVA, GALINA
|
VANDERBILT UNIVERSITY
|
TN
|
$409,128
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL070227-15
|
|
HL-Development and Pharmacology of novel lipidic rAHF and biotherapeutics
|
BALU-IYER, SATHY
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
NY
|
$395,244
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL131143-03
|
|
Development of a gene therapy approach to treat acute lung injury using a preclinical, large animal model
|
DEAN, DAVID
|
UNIVERSITY OF ROCHESTER
|
NY
|
$759,156
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI128862-02
|
|
Biosynthesis and medicinal chemistry of the capuramycin antimycobacterial antibiotics
|
VAN LANEN, STEVEN
|
UNIVERSITY OF KENTUCKY
|
KY
|
$200,000
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA188134-02
|
|
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$615,683
|
|
Orphan Drug
|
2018
|
NIGMS
|
5R01GM116823-03
|
|
Neutrophil-mediated Drug Delivery
|
WANG, ZHENJIA
|
WASHINGTON STATE UNIVERSITY
|
WA
|
$339,750
|
|
Orphan Drug
|
2018
|
NICHD
|
5R21HD087760-02
|
|
Targeting SHP2 phosphatase for chemoprevention of leukemic progression in Noonan syndrome
|
QU, CHENG-KUI
|
EMORY UNIVERSITY
|
GA
|
$234,000
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL130871-03
|
|
Development of highly efficient factor VIII mini-gene therapy
|
XIAO, WEIDONG
|
TEMPLE UNIV OF THE COMMONWEALTH
|
PA
|
$482,625
|
|
Orphan Drug
|
2018
|
NIAMS
|
5R01AR066003-04
|
|
MKP5 in Dystrophic Muscle Disease
|
BENNETT, ANTON
|
YALE UNIVERSITY
|
CT
|
$392,351
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127581-02
|
|
Parasite-specific proteasome inhibitors to combat multi-drug resistant malaria
|
BOGYO, MATTHEW
|
STANFORD UNIVERSITY
|
CA
|
$215,097
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI128737-02
|
|
Rapid development of replication-controlled vaccinia virus vectors for vaccines and therapeutics with single or double safety features
|
VERARDI, PAULO
|
UNIVERSITY OF CONNECTICUT STORRS
|
CT
|
$193,993
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA055349-24
|
|
Mechanisms of action of a TCR-like antibody to WT1
|
SCHEINBERG, DAVID
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$384,667
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA174861-05
|
|
Novel Theranostics for Pancreatic Cancer
|
DAVYDOVA, JULIA
|
UNIVERSITY OF MINNESOTA
|
MN
|
$319,031
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA196215-03
|
|
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDAC
|
YAMAMOTO, MASATO
|
UNIVERSITY OF MINNESOTA
|
MN
|
$351,132
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA205633-02
|
|
Inhibition of Oral Tumorigenesis by Antitumor B
|
YOU, MING
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$504,001
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA211337-02
|
|
Molecular Imaging Markers for Glutaminolysis in Breast Cancer
|
MANKOFF, DAVID
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$382,319
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA211681-02
|
|
USP7 inhibitors for the treatment of multiple myeloma
|
BUHRLAGE, SARA
|
DANA-FARBER CANCER INST
|
MA
|
$504,721
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA212649-02
|
|
Personalized vaccine for patients with AML
|
AVIGAN, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$721,179
|
|
Orphan Drug
|
2018
|
NICHD
|
5UG1HD083166-04
|
|
Collaborative Research to Validate Biomarkers of Pediatric ARDS
|
MCQUILLEN, PATRICK
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$272,217
|
|
Orphan Drug
|
2018
|
NICHD
|
5R01HD064727-08
|
|
SLOS and Neuronal Oxidative Stress
|
PORTER, NED
|
VANDERBILT UNIVERSITY
|
TN
|
$432,819
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL135114-02
|
|
Clinical and mechanistic role of HDGF in pulmonary hypertension
|
EVERETT, ALLEN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$638,631
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127489-02
|
|
Treatment and Prevention of Systemic Candidiasis
|
NOBLE, SUZANNE
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$229,936
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI123024-03
|
|
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infection
|
METCALFE, JOHN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$696,561
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI127711-02
|
|
Modulation of Host Cell Environment by Mycobacterial PE/PPE Proteins
|
LEE, SUNHEE
|
DUKE UNIVERSITY
|
NC
|
$553,074
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA203348-03
|
|
Blocking NK cell shedding of CD16a to increase cancer cell killing
|
WALCHECK, BRUCE
|
UNIVERSITY OF MINNESOTA
|
MN
|
$447,909
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA212600-02
|
|
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer
|
BRODY, JONATHAN
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$372,748
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA211016-02
|
|
Immune Impact on Cancer Chemoresistance
|
ZOU, WEIPING
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$611,871
|
|
Orphan Drug
|
2018
|
NEI
|
5R01EY024249-04
|
|
A High Content Screening Approach for the Retinal Degenerative Diseases
|
BERLINICKE, CYNTHIA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$405,000
|
|
Orphan Drug
|
2018
|
NIA
|
5R01AG052496-02
|
|
Emotion network dysfunction and decline in early frontotemporal dementia
|
STURM, VIRGINIA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$551,852
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI085051-09
|
|
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition
|
SCHIFFER, CELIA
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$588,464
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI123244-03
|
|
Mucosal Vaccines for Brucellosis
|
PASCUAL, DAVID
|
UNIVERSITY OF FLORIDA
|
FL
|
$436,758
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA169784-05
|
|
Genetic Dissection of Acute Myeloid Leukemia.
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$355,993
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA196263-03
|
|
Peripherally-restricted cannabinoids for cancer and chemotherapy-induced pain
|
SCHMIDT, BRIAN
|
NEW YORK UNIVERSITY
|
NY
|
$492,705
|
|
Orphan Drug
|
2018
|
NIDCR
|
5R21DE025920-02
|
|
Comprehensive Identification of FXR1 Targets Using pSILAC-BONCAT Proteomics
|
PALANISAMY, VISWANATHAN
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$186,875
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL132153-02
|
|
Functional Impact of Col18a1/Endostatin Variants in PAH
|
DAMICO, RACHEL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$644,325
|
|
Orphan Drug
|
2018
|
NIDCR
|
5F31DE026682-02
|
|
Immunomodulatory Nanoparticles in Combination with Immune Checkpoint Inhibitors for the Systemic Treatment of Immunosuppressive HPV Associated Oropharyngeal Cancer
|
NEWTON, JARED
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$45,324
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI128480-02
|
|
Chemical genetic screening to identify synergistic inhibitors of malaria parasite cell cycle regulators
|
DURAISINGH, MANOJ
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
MA
|
$199,010
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA065823-22
|
|
Characterizing the landscape of resistance and persistence mechanisms in CML
|
DRUKER, BRIAN
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$329,175
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA181658-04
|
|
MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors
|
LARSON, ANDREW
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$451,626
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA204446-02
|
|
Antivascular ultrasound therapy of primary liver neoplasia
|
SEHGAL, CHANDRA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$415,179
|
|
Orphan Drug
|
2018
|
NCI
|
5R21CA205564-02
|
|
A new class of CSF-1R radioligands for monitoring glioblastoma progression and therapy
|
CHIN, FREDERICK
|
STANFORD UNIVERSITY
|
CA
|
$171,060
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA204136-02
|
|
Credentialing murine models for glioblastoma preclinical drug development
|
MILLER, CHRISTOPHER
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$605,422
|
|
Orphan Drug
|
2018
|
NCATS
|
1UG3TR002151-01
|
|
Integrated Microphysiological System of Cerebral Organoid and Blood Vessel for Disease Modeling and Neuropsychiatric Drug screening
|
LEONG, KAM
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$1,177,110
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI118389-04
|
|
Vaccines Against Botulism
|
BARBIERI, JOSEPH
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$585,553
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL132213-02
|
|
Role of Cardiac Troponin in Health and Disease
|
DAVIS, JONATHAN
|
OHIO STATE UNIVERSITY
|
OH
|
$377,595
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI121993-02
|
|
Multifactor mRNA Mediated T Cell Reprogramming for Systemic Lupus Erythematosus
|
KATZ, SAMUEL
|
YALE UNIVERSITY
|
CT
|
$167,500
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127582-02
|
|
A Systems Biology Approach for Targeted Drug Discovery for Leishmaniasis
|
IBBA, MICHAEL
|
OHIO STATE UNIVERSITY
|
OH
|
$205,141
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127591-02
|
|
Development of Novel Therapeutics for Leishmaniasis
|
LANDFEAR, SCOTT
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$189,589
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI123876-02
|
|
Development of a method for visual detection of Mycobacterium tuberculosis complex
|
GERASIMOVA, YULIA
|
UNIVERSITY OF CENTRAL FLORIDA
|
FL
|
$177,776
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127503-02
|
|
Targeting trypanosomatid deoxyhypusine synthase
|
PHILLIPS, MARGARET
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$202,500
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI127654-02
|
|
Generation of Robust Resident Memory T cells in Barrier Tissues through Skin Vaccination
|
KUPPER, THOMAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$1,010,181
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA120813-12
|
|
Modulation of Microglia and T Cell Interactions in Malignant Glioma
|
HEIMBERGER, AMY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$288,000
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA183444-05
|
|
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies
|
BYRD, JOHN
|
OHIO STATE UNIVERSITY
|
OH
|
$501,285
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA142874-08
|
|
Targeting PML for Leukemia Therapy
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$457,619
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA184088-04
|
|
Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
|
KABANOV, ALEXANDER
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$344,549
|
|
Orphan Drug
|
2018
|
NIBIB
|
5R01EB019458-04
|
|
Pre-clinical quantitation of ovarian cancer tumor burden using Magnetic Particle Imaging and non-dilutive cell labeling
|
CONOLLY, STEVEN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$462,841
|
|
Orphan Drug
|
2018
|
NHLBI
|
5K08HL130592-02
|
|
Functional Characterization of Phosphodiesterase 1 in Single Ventricle Heart Disease
|
NAKANO, STEPHANIE
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$165,240
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL134905-02
|
|
Anastrozole in Pulmonary Arterial Hypertension (AIPH2) - CCC (Lead)
|
KAWUT, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$1,114,479
|
|
Orphan Drug
|
2018
|
NINDS
|
5K08NS099484-02
|
|
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma
|
RAHMAN, MARYAM
|
UNIVERSITY OF FLORIDA
|
FL
|
$181,980
|
|
Orphan Drug
|
2018
|
NCI
|
5R03CA212877-02
|
|
Tumor Molecular Profiling and Response to Immunotherapy in Advanced Biliary Cancers
|
KELLEY, R.
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$79,250
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI128362-02
|
|
Structure- and ligand-based design of new IspD-targeting antimalarials
|
CARLIER, PAUL
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
VA
|
$185,600
|
|
Orphan Drug
|
2018
|
NIGMS
|
5SC3GM112543-04
|
|
Aberrant Epigenetic Repression in Esophageal Malignancy
|
LIN, CHIN-HSING
|
UNIVERSITY OF TEXAS SAN ANTONIO
|
TX
|
$110,250
|
|
Orphan Drug
|
2018
|
NIGMS
|
5R01GM079656-11
|
|
Comparative genomics of protein structure and function
|
LICHTARGE, OLIVIER
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$396,958
|
|
Orphan Drug
|
2018
|
NCI
|
5K25CA201545-02
|
|
Development of microfluidic blood-brain tumor barrier model to screen chemotherapeutic strategies for breast cancer brain metastases
|
LEE, WON JAE
|
STANFORD UNIVERSITY
|
CA
|
$157,167
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI128097-02
|
|
Development of Human Broadly Neutralizing Monoclonal Antibodies Against New World Arenaviruses​
|
MARTINEZ-SOBRIDO, LUIS
|
UNIVERSITY OF ROCHESTER
|
NY
|
$277,659
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI123501-02
|
|
Mechanism-based targeting of bacterial topoisomerases
|
MAIZELS, NANCY
|
UNIVERSITY OF WASHINGTON
|
WA
|
$243,323
|
|
Orphan Drug
|
2018
|
NCI
|
5R00CA183914-05
|
|
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment
|
WAN, LIXIN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$148,607
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA175772-05
|
|
Targeting tumor-stromal interaction for pancreatic cancer therapy
|
SINGH, AJAY
|
UNIVERSITY OF SOUTH ALABAMA
|
AL
|
$314,363
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA195503-04
|
|
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
FL
|
$363,623
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA190498-04
|
|
gp130 as a novel therapeutic target in ovarian cancer
|
NEAMATI, NOURI
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$376,320
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA172724-04
|
|
Novel Strategies to Target Leukemia-Stromal Interactions
|
PELICANO, HELENE
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA213448-02
|
|
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody
|
POIRIER, JOHN
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$699,927
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA211175-02
|
|
Averting recurrent and resistant ovarian tumors
|
WANG, QIEN
|
OHIO STATE UNIVERSITY
|
OH
|
$451,109
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL031823-28
|
|
Heme synthesis, use and trafficking during erythropoiesis
|
ABKOWITZ, JANIS
|
UNIVERSITY OF WASHINGTON
|
WA
|
$415,875
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA142665-08
|
|
Glucocorticoids in Lymphoblastic Leukemia
|
RELLING, MARY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$487,994
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI093380-06
|
|
Malaria Topoisomerase inhibitors
|
RATHOD, PRADIPSINH
|
UNIVERSITY OF WASHINGTON
|
WA
|
$490,036
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI128090-02
|
|
Engineered Dengue EDIIIs as Broad Immunogens
|
LAI, JONATHAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
NY
|
$254,193
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA014236-44
|
5328
|
Neuro-Oncology Research Program
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
NC
|
$40,785
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA014236-44
|
5329
|
Women's Cancer Research Program
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
NC
|
$36,366
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA014236-44
|
5330
|
Hematologic Malignancies and Cellular Therapies Research Program
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
NC
|
$40,785
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA014236-44
|
5331
|
Solid Tumor Therapeutics Research Program
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
NC
|
$40,785
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI119022-04
|
|
Structure and mechanism of the ESX secretion system from pathogenic mycobacteria
|
KOROTKOV, KONSTANTIN
|
UNIVERSITY OF KENTUCKY
|
KY
|
$376,250
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA207401-02
|
|
Increasing HPV vaccine uptake in community-based pediatric practices
|
HULL, PAMELA
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
TN
|
$565,206
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA023108-39
|
5370
|
Cancer Imaging & Radiobiology (CIR)
|
PAULSEN, KEITH
|
DARTMOUTH COLLEGE
|
NH
|
$72,840
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA023108-39
|
5371
|
Immunology & Cancer Immunotherapy (ICI)
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
NH
|
$72,409
|
|
Orphan Drug
|
2018
|
NIAMS
|
5R03AR068118-03
|
|
The Cytosolic Nucleic Acid-Sensing Pathway and Skin Antiviral Innate Immunity
|
DENG, LIANG
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$85,700
|
|
Orphan Drug
|
2018
|
NIAAA
|
5P50AA011999-20
|
8467
|
Functional Dissection of EtOH-med Self-renew of Liver Tumor-Int Cells via TLR4
|
MACHIDA, KEIGO
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$203,571
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI129531-02
|
|
Discovering host factors impacting ZIKV infection via forward genetic screens
|
BATES, PAUL
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$195,138
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI104488-05
|
|
A Nurse Case Management Intervention to Improve MDR-TB/HIV Coinfection Outcomes
|
FARLEY, JASON
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$1
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI114873-04
|
|
ZAP isoforms in innate immunity-the long, the short and the extra-long of it all
|
MACDONALD, MARGARET
|
ROCKEFELLER UNIVERSITY
|
NY
|
$423,750
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI127724-02
|
|
Development of Selective Ribosomal P-site Inhibitors
|
LOOPER, RYAN
|
UNIVERSITY OF UTAH
|
UT
|
$379,792
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R00HL118157-05
|
|
Regulation of Erythroid Terminal Differentiation by Long Noncoding RNAs
|
HU, WENQIAN
|
MAYO CLINIC ROCHESTER
|
MN
|
$249,000
|
|
Orphan Drug
|
2018
|
NINDS
|
5R01NS091575-03
|
|
Targeting the Ubiquitin Proteasome System to Treat Spinal Muscular Atrophy
|
BURNETT, BARRINGTON
|
HENRY M. JACKSON FDN FOR THE ADV MIL/MED
|
MD
|
$303,692
|
|
Orphan Drug
|
2018
|
NIAID
|
5K08AI127908-02
|
|
Translational modeling of individual- and population-level outcomes of novel tuberculosis drug regimens
|
KENDALL, EMILY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$194,681
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI114674-04
|
|
The Consequences of Reinfection with M. tuberculosis
|
FLYNN, JOANNE
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$744,863
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA006516-53
|
5399
|
Program 4: Leukemia
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$74,743
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA006516-53
|
5400
|
Program 6: Lymphoma and Myeloma
|
SHIPP, MARGARET
|
DANA-FARBER CANCER INST
|
MA
|
$73,653
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA006516-53
|
5405
|
Program 11: Cancer Immunology
|
SHARPE, ARLENE
|
HARVARD MEDICAL SCHOOL
|
MA
|
$77,721
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA006516-53
|
5409
|
Program 30: Neuro-Oncology
|
STILES, CHARLES
|
DANA-FARBER CANCER INST
|
MA
|
$75,340
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA006516-53
|
5410
|
Program 32: Gastrointestinal Malignancies
|
FUCHS, CHARLES
|
DANA-FARBER CANCER INST
|
MA
|
$73,899
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA006516-53
|
5413
|
Program 52: Kidney Cancer
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$93,630
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA187219-03
|
|
Peptide vaccine immunotherapy for children with recurrent low-grade astrocytomas
|
POLLACK, IAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$352,786
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA213423-02
|
|
High-frequency Irreversible Electroporation (H-FIRE) combinatorial GBM treatment
|
DAVALOS, RAFAEL
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
VA
|
$359,874
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA213278-02
|
|
Reprogramming Tumor Microenvironment by Nanoparticle
|
MUKHERJEE, PRIYABRATA
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$338,550
|
|
Orphan Drug
|
2018
|
NIGMS
|
5R01GM113236-04
|
|
Exosomes and HB-EGF in Stem Cell-Mediated Therapy for Necrotizing Enterocolitis
|
BESNER, GAIL
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$284,050
|
|
Orphan Drug
|
2018
|
NHLBI
|
5R01HL079118-12
|
|
Roles of Mre11 in Lymphocyte Development and DNA Repair
|
FERGUSON, DAVID
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$380,944
|
|
Orphan Drug
|
2018
|
NHLBI
|
5UG1HL135665-02
|
|
Pediatric Heart Network Regents of the University of Michigan
|
GOLDBERG, CAREN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$340,964
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA150190-07
|
|
Targeting Pancreatic Cancer Using Peptide Chemistry: From Bench to Bedside
|
MUKHOPADHYAY, DEBABRATA
|
MAYO CLINIC JACKSONVILLE
|
FL
|
$586,058
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA151354-07
|
|
Biological Validation of Candidate Myeloma Driver Genes
|
JANZ, SIEGFRIED
|
UNIVERSITY OF IOWA
|
IA
|
$590,938
|
|
Orphan Drug
|
2018
|
NCI
|
5R01CA211646-02
|
|
Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor
|
ZETTER, BRUCE
|
BOSTON CHILDREN'S HOSPITAL
|
MA
|
$411,481
|
|
Orphan Drug
|
2018
|
NIBIB
|
5R00EB016690-05
|
|
Role of cerebrospinal fluid dynamics in brain drug delivery
|
SY, JAY
|
RUTGERS, THE STATE UNIV OF N.J.
|
NJ
|
$237,529
|
|
Orphan Drug
|
2018
|
NICHD
|
5R01HD084500-04
|
|
Markers of Disease Progression in MECP2 Duplication Syndrome
|
PETERS, SARIKA
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
TN
|
$326,652
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127639-02
|
|
Novel Therapeutics for Treatment of River Blindness and Lymphatic Filariasis
|
SAKANARI, JUDY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$195,658
|
|
Orphan Drug
|
2018
|
NEI
|
5R01EY013433-11
|
|
A Ribozyme Rescue Strategy for Autosomal Dominant Retinitis Pigmentosa
|
SULLIVAN, JOHN
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
NY
|
$378,000
|
|
Orphan Drug
|
2018
|
NIGMS
|
5R00GM112877-03
|
|
Understanding Epstein Barr virus oncogenicity through non-coding RNA structure
|
MOSS, WALTER
|
IOWA STATE UNIVERSITY
|
IA
|
$249,000
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI127988-02
|
|
Targeting Angiogenesis Pathways for Therapeutic Protection against Dengue
|
SHRESTA, SUJAN
|
LA JOLLA INST FOR ALLERGY & IMMUNOLGY
|
CA
|
$225,000
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI130454-02
|
|
Mechanisms of Innate Immune Evasion by Mycobacterium Tuberculosis
|
PHILIPS, JENNIFER
|
WASHINGTON UNIVERSITY
|
MO
|
$567,384
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA008748-52
|
7554
|
Animal Imaging
|
LEKAYE, CARL
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$247,787
|
|
Orphan Drug
|
2018
|
NCI
|
5P30CA008748-52
|
7572
|
Research Pharmacy
|
MULLER, RAYMOND
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$206,346
|
|
Orphan Drug
|
2018
|
NIAID
|
5R01AI116723-04
|
|
Optimization of Antischistosomal Chemotypes
|
VENNERSTROM, JONATHAN
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$598,659
|
|
Orphan Drug
|
2018
|
NIAID
|
5R21AI128087-02
|
|
Optimizing Gene Editing in Primary Human B Cells for Therapy and Research
|
MORIARITY, BRANDEN
|
UNIVERSITY OF MINNESOTA
|
MN
|
$191,875
|
|
